Evidence map›Paper›PMID 28768052›Full record

ArticleBritish journal of pharmacology2017

Cardioprotective effects of 5-hydroxymethylfurfural mediated by inhibition of L-type Ca

G Wölkart, A Schrammel, C N Koyani, S Scherübel, K Zorn-Pauly, E Malle, B Pelzmann, M Andrä, A Ortner, B Mayer

Open access · hybridAbstract read
In one paragraph

Article in British journal of pharmacology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
1.8field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 30 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Pharmaceuticals (Basel, Switzerland) · 2023
    Article
  5. Article
  6. Article
  7. Article
  8. Protective Effect ofAntioxidants (Basel, Switzerland) · 2021
    Article
  9. Article
  10. Modulation of Hb-OClinical nutrition (Edinburgh, Scotland) · 2021
    Review
  11. Article
  12. Oxidative medicine and cellular longevity · 2020
    Article
  13. Article
  14. Regulation of CaCell calcium · 2019
    Article
  15. Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

G WölkartInstitute of Pharmaceutical Sciences, Department of Pharmacology and Toxicology, University of Graz, Graz, Austria.
A SchrammelInstitute of Pharmaceutical Sciences, Department of Pharmacology and Toxicology, University of Graz, Graz, Austria.
C N KoyaniInstitute of Molecular Biology and Biochemistry, Medical University of Graz, Graz, Austria.
S ScherübelInstitute of Biophysics, Medical University of Graz, Graz, Austria.
K Zorn-PaulyInstitute of Biophysics, Medical University of Graz, Graz, Austria.
E MalleInstitute of Molecular Biology and Biochemistry, Medical University of Graz, Graz, Austria.
B PelzmannInstitute of Biophysics, Medical University of Graz, Graz, Austria.
M AndräDepartment of Thoracic and Cardiovascular Surgery, Klinikum Klagenfurt, Klagenfurt, Austria.
A OrtnerInstitute of Pharmaceutical Sciences, Department of Pharmaceutical Chemistry, University of Graz, Graz, Austria.ORCID http://orcid.org/0000-0001-8604-1273
B MayerInstitute of Pharmaceutical Sciences, Department of Pharmacology and Toxicology, University of Graz, Graz, Austria.ORCID http://orcid.org/0000-0002-2921-3494
Medical University of Graz · ATUniversity of Graz · ATKlinikum Klagenfurt · AT

Funding

Austrian Science Fund FWF P 24946
6 · The paper itself

Abstract

background and purposeThe antioxidant 5-hydroxymethylfurfural (5-HMF) exerts documented beneficial effects in several experimental pathologies and is currently tested as an antisickling drug in clinical trials. In the present study, we examined the cardiovascular effects of 5-HMF and elucidated the mode of action of the drug. EXPERIMENTAL APPROACH: The cardiovascular effects of 5-HMF were studied with pre-contracted porcine coronary arteries and rat isolated normoxic-perfused hearts. Isolated hearts subjected to ischaemia/reperfusion (I/R) injury were used to test for potential cardioprotective effects of the drug. The effects of 5-HMF on action potential and L-type Ca KEY

results5-HMF relaxed coronary arteries in a concentration-dependent manner and exerted negative inotropic, lusitropic and chronotropic effects in rat isolated perfused hearts. On the other hand, 5-HMF improved recovery of inotropic and lusitropic parameters in isolated hearts subjected to I/R. Patch clamp experiments revealed that 5-HMF inhibits L-type Ca CONCLUSIONS AND IMPLICATIONS: Our data revealed a cardioprotective effect of 5-HMF in I/R that is mediated by inhibition of L-type Ca

Indexed as

AnimalsCalcium Channel BlockersCalcium Channels, L-TypeCardiotonic AgentsCoronary VesselsFemaleFuraldehydeGuinea PigsHeart VentriclesMaleMyocytes, CardiacRats, Sprague-DawleyReperfusion InjurySwine5-hydroxymethylfurfuralCalcium Channel BlockersCalcium Channels, L-TypeCardiotonic AgentsFuraldehyde

Identifiers

PMID28768052
PMCPMC5610158
OpenAlexW2739607387

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.